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LETTER TO THE EDITOR
Nocardiosis in a renal transplant recipient following rituximab
preconditioning
TANYA R. FLOHR, COSTI D. SIFRI, KENNETH L. BRAYMAN, KLAUS D. HAGSPIEL,
ROBERT G. SAWYER, TIMOTHY L. PRUETT & HUGO J. R. BONATTI
Sir,
With great interest we read the recent article
‘Pulmonary nocardiosis with brain abscess in a
sensitized kidney transplant recipient with history
of repeated graft loss and human leukocyte antigen
HLA-antibody depletion treatment*a case report’
by Ali-Reza Biglarnia et al. (1). This report is
important in the light of an increased exposure of
renal transplant recipients to more intense immuno-
suppression, in particular to depleting antibodies
such as rituximab. Rituximab is unique, as in
contrast to antithymocyte globulin (ATG), muro-
munab OKT3, and alemtuzumab it targets B cells
(2) but may cause profound hypogammaglobuline-
mia. We would like to add another case of nocar-
diosis after renal transplantation (RT) and exposure
to rituximab that largely mimics the case reported by
Biglarnia and should support the findings and
emphasize the risk for opportunistic infections in
such patients.
Our patient was a 45-year-old female with end
stage renal disease secondary to streptococcal glo-
merulonephritis. She underwent living related RT in
1978 but ceased taking her immunosuppression
during the early 1990s for an unknown period. In
1997, she presented with an elevation in her serum
creatinine from 1.5 to 5.0 mg/dL. This non-com-
pliance-associated rejection was initially treated with
a course of methylprednisolone (500 mg daily for
three doses), then with a course of OKT3 (5 mg
daily for five days). The rejection could not be
reversed, and she was started on hemodialysis in
1998. The patient tested repeatedly positive for
preformed panel-reactive antibodies (PRA) with
high titers, and on several occasions the donor/
recipient cross-match was positive, preventing a
cadaveric RT. The option for living related donation
was evaluated; however, the cross-match was again
incompatible. Therefore, the patient underwent
preconditioning for RT with rituximab (375 mg/
m
2), intravenous immunoglobulin (IVIG) at a dose
of 0.5 4.0 mg/kg/min, and whole plasma exchange
(WPE). During the waiting time for RT she was
maintained on mycophenolate mofetil (MMF) at a
dose of 2 g/day. Her subsequent titer of PRAs was
found to be suitable to proceed with RT. Living
related RT from a cousin was performed without
complication in 2006, and immunosuppression
consisted of ATG induction (1.5 mg/kg for three
days) followed by tacrolimus (TAC) with trough
levels of 6 12 ng/mL, with continuation of MMF
and a steroid taper. Two weeks post RT, a biopsy
revealed humoral rejection. She was treated with
ATG, IVIG, and nine courses of WPE. Rejection
resolved, and she was discharged with stable graft
function. Pneumocystis jirovecii prophylaxis consisted
of dapsone due to her sulfa allergy; She was
hospitalized multiple times for anasarca, urinary
tract infection, and pneumonia. Despite several
attempts to counsel the patient, she continued
smoking and missed several follow-up appointments.
Three months post RT she developed another
episode of pneumonia presenting with shortness of
breath, cough, and fever. Chest X-ray revealed a left
upper lobe lesion consistent with infection in the
context of the clinical history. No pathogen could be
isolated from sputum. She received a 10-day course
of empiric therapy with linezolid (600 mg daily) and
ciprofloxacin (500 mg twice daily), and immuno-
suppression was temporarily reduced. She rapidly
improved and was discharged with stable graft
function. Two months later, she again deteriorated;
her left upper lobe lesion appeared unresolved and
cavitary on chest X-ray and CT scan (Figure 1).
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nova. She was desensitized and started on twice
daily double-strength trimethoprim/sulfamethoxa-
zole (TMPS); immunosuppression was again tem-
porarily reduced. She was discharged with resolved
respiratory symptoms and stable graft function,
however, again deteriorated requiring readmission
six months after first diagnosis of nocardiosis. She
developed respiratory failure requiring mechanical
ventilation. Nocardia could not be isolated, however,
TMPS was continued. She again improved and was
discharged with stable graft function. Subsequently,
she was hospitalized another two times for respira-
tory infections. Her chest CT scan continued to
reveal a lung lesion with slow resolution. She is
currently alive with good graft function, no further
rejection episodes and no signs of recurrent nocar-
diosis.
Similar to the reported case by Biglarnia et al.
our patient had a re-RT, and the first RT was
complicated by steroid-resistant rejection and
OKT3 treatment. In addition both patients had
elevated PRA and underwent preconditioning using
WPE and rituximab. Both received TAC, MMF, and
steroids for maintenance immunosuppression. Our
patient may have received even more intense im-
munosuppression (ATG versus interleukin IL-2
receptor antagonist induction), and in addition she
had rejection requiring a second course of ATG and
WPE. On the other hand our patient was 14 years
younger. Both patients had no prophylaxis against
Nocardia as their Pneumocystis jirovecii prophylaxis
included dapsone and inhaled pentamidine. Recent
findings by the Pittsburgh group suggested that in a
subset of patients, TMPS may be ineffective in terms
of prophylaxis against Nocardia (3). The application
of linezolid for pneumonia may have temporarily
controlled Nocardia growth. This new agent may be
a good treatment option in transplant recipients, and
one patient in the publication from the Innsbruck
group was successfully treated with linezolid (3). In
our patient, we assume that the continuous smoking
was a significant contributor. Nocardiosis has been
reported in a RTrecipient who was a smoker (4). We
have recently encountered an increasing number of
transplant recipients with nocardiosis. In addition,
extrapulmonary manifestations have become more
common, and species other than Nocardia asteroides
are on the rise. Our patient had only pulmonary
involvement in contrast to the previously reported
case, and in both cases non-asteroides Nocardia were
the causing organism (Nocardia nova and Nocardia
farcinica). A common denominator in 11 transplant
recipients who developed nocardiosis between 1995
and 2008 at our center was the use of depleting
antibodies. Transplant physicians should be aware of
this rare infection and include nocardiosis in the
differential diagnosis in patients presenting with
pneumonia.
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Figure 1. Chest X-ray (A) and CT scan (B) show left lobe inﬁltrates.
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